Agree with you Danielguda 1,the dose escalation is a big rise in...

Agree with you Danielguda 1,
the dose escalation is a big rise in cohort 3 and 4.
The 3rd cohort is two and a half times the dose in the second cohort.
The 4th cohort will be X5 of the second cohort, assuming everything passes safety wise in the 3rd cohort.
Jennifer said that the were not expecting any efficiency in the first two cohorts because of the very low dose, but the sigh's are already there, so they are very excited at the moment with the way it's going. Time will tell, but have a good read of the analyst's in the last few months of CHM.
The positives and negatives in the reports.
I'm liking my odds.

RAAS, research as a service. = valuation 0.74/share

Diamond Equity Research.= valuation 0.94/share

Independent Investment Research= valuation 0.76/share


Edison=0.97/share

and Bioshares have told there subscribers that CHM is a Class A speculative Buy.
Speculative Buy ñ Class A
These stocks will have more than one technology, product or
investment in development, with perhaps those same technologies offering multiple opportunities. These features, coupled to the presence of alliances, partnerships and scientific advisory boards, INDICATE THE STOCK IS LESS RISKY THAN OTHER BIOTECH STOCKS.
Hoping to get my full allocation in the cap raise and the extra I put in for. GLTA